Literature DB >> 17187499

Regulators of G-protein-coupled receptor-G-protein coupling: antidepressants mechanism of action.

Gabriel Schreiber1, Sofia Avissar.   

Abstract

There is a significant gap between advances in medication for mental disorders and the present static situation of biological diagnosis and monitoring treatment. The system of neural transmission and signal transduction is a complicated, highly regulated cascade of biochemical events. Growing evidence suggests that receptor-G-protein coupling may be involved in both the pathogenesis and treatment of mood disorders. Our knowledge concerning the basic mechanisms underlying the phenomenon of desensitization, internalization, downregulation and resensitization of the G-protein-coupled receptor has been advanced during the last decade. The present review discusses the possible involvement of regulators of G-protein-coupled receptor-G-protein coupling: beta-arrestins, G-protein-coupled receptor kinases and phosducin-like proteins, as well as beta-arrestins alternative signaling events, in the pathophysiology, diagnosis and treatment monitoring of mood disorders and in the mechanism of action of antidepressant medications.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17187499     DOI: 10.1586/14737175.7.1.75

Source DB:  PubMed          Journal:  Expert Rev Neurother        ISSN: 1473-7175            Impact factor:   4.618


  5 in total

1.  An epigenome-wide methylation study of healthy individuals with or without depressive symptoms.

Authors:  Mihoko Shimada; Takeshi Otowa; Taku Miyagawa; Tadashi Umekage; Yoshiya Kawamura; Miki Bundo; Kazuya Iwamoto; Tempei Ikegame; Mamoru Tochigi; Kiyoto Kasai; Hisanobu Kaiya; Hisashi Tanii; Yuji Okazaki; Katsushi Tokunaga; Tsukasa Sasaki
Journal:  J Hum Genet       Date:  2018-01-05       Impact factor: 3.172

2.  Na+/K+-ATPase level and products of lipid peroxidation in live cells treated with therapeutic lithium for different periods in time (1, 7, and 28 days); studies of Jurkat and HEK293 cells.

Authors:  Miroslava Vosahlikova; Lenka Roubalova; Hana Ujcikova; Martina Hlouskova; Stanislav Musil; Martin Alda; Petr Svoboda
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2019-02-21       Impact factor: 3.000

3.  GABAergic control of depression-related brain states.

Authors:  Bernhard Luscher; Thomas Fuchs
Journal:  Adv Pharmacol       Date:  2015-01-14

4.  [18F]F15599, a novel 5-HT1A receptor agonist, as a radioligand for PET neuroimaging.

Authors:  Laëtitia Lemoine; Mathieu Verdurand; Bernard Vacher; Elodie Blanc; Didier Le Bars; Adrian Newman-Tancredi; Luc Zimmer
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-09-30       Impact factor: 9.236

5.  Neurogenesis-dependent and -independent effects of fluoxetine in an animal model of anxiety/depression.

Authors:  Denis J David; Benjamin Adam Samuels; Quentin Rainer; Jing-Wen Wang; Douglas Marsteller; Indira Mendez; Michael Drew; Douglas A Craig; Bruno P Guiard; Jean-Philippe Guilloux; Roman P Artymyshyn; Alain M Gardier; Christophe Gerald; Irina A Antonijevic; E David Leonardo; René Hen
Journal:  Neuron       Date:  2009-05-28       Impact factor: 17.173

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.